reata pharmaceuticals inc stock

Over the past year insiders sold US78m worth of Reata Pharmaceuticals Inc. NASDAQRETA stock at an average price of US142 per share allowing them to get the most out of their moneyAfter the stock price dropped 14 last week the companys market value declined by US171m but insiders were able to mitigate their losses.

Why Reata Pharmaceuticals Stock Got Absolutely Crushed On Thursday The Motley Fool

Reata Pharmaceuticals 3291 008 024 Watch.

. Latest Reata Pharmaceuticals Inc RETA Stock News. Reata Pharmaceuticals Inc. RETA Reports Q4 Loss Lags Revenue Estimates Reata.

Cl A stock news by MarketWatch. Diabetic peripheral neuropathic pain. Find real-time RETA - Reata Pharmaceuticals Inc stock quotes company profile news and forecasts from CNN Business.

Real-time trade and investing ideas on Reata Pharmaceuticals RETA from the largest community of traders and investors. We expect to complete submission of the NDA by the end of the first quarter of 2022. Over the past year the SP 500 is up 1527 while RETA has fallen -7641.

Do the numbers hold clues to what lies ahead for the. As of March 30 2022 Reata Pharmaceuticals Inc had a 13 billion market capitalization compared to the Biotechnology Medical Research median of 1587 million Reata Pharmaceuticals Incs stock is up 242 in 2022 down 109 in the previous five trading days and down 690 in the past. Is a clinical-stage biopharmaceutical company that is focused on identifying developing and commercializing therapies.

Ad Horizon Is A Leading High-Growth Biopharma Company. Bardoxolone Bardoxolone methyl. Reata Pharmaceuticals Stock Forecast Price News 3477 -173 -474 As of 04142022 0204 PM ET Todays Range 3425 3486 50-Day Range 2481 3960 52-Week Range 2271 15341 Volume 11748 shs Average Volume 877177 shs Market Capitalization 127 billion PE Ratio NA Dividend Yield NA Beta 114 Profile Analyst Ratings Chart.

Reata defended at Citi after FDA comments on ALS drug Benzinga 21d 35 Stocks Moving In Mondays Mid-Day Session Gainers Hycroft Mining Holding Corporation NASDAQ. Learn More About Our Differentiated RD Strategy. RETA shares rallied 145 in the last trading session to close at 3454.

Is a clinical-stage biopharmaceutical company that is focused on identifying developing and commercializing therapies. Reata Pharmaceuticals Inc. 3 On February 25 2022 we received a CRL from the FDA.

Get the latest Reata Pharmaceuticals Inc RETA detailed stock. If you experience any issues with this process please contact us for further assistance. View real-time stock prices and stock quotes for a full financial overview.

ET The biopharmaceutical company got some potentially. Primary metrics and data points about Reata Pharmaceuticals Inc. RETA stock price quote stock graph.

We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. RETA has fallen -105 from the previous closing price of 2726 on volume of 257510 shares. Reata Pharmaceuticals Shares Rise 22 After Fourth Quarter Earnings By Sam Boughedda Zacks Reata Pharmaceuticals Inc.

HYMC jumped 571 to 196. RETA delivered earnings and revenue surprises of -173 and 3329 respectively for the quarter ended December 2021. Rooms Shows Rankings Earnings Newsletters Shop.

This move can be attributable to notable volume with a higher number. 1 Rolling NDA submission initiated in the first quarter of 2022. Get the latest Reata Pharmaceuticals Inc RETA real-time quote historical performance charts and other financial information to help you make more.

Reata Pharmaceuticals Inc RETA stock has fallen -385 while the SP 500 has fallen -092 as of 149 PM on Friday Jan 21. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe life-threatening diseases with therapies. Mar 30 2022 721AM EDT R eata Pharmaceuticals Inc.

At Reata Pharmaceuticals Inc we promise to treat your data with respect and will not share your information with any third party. RETA Complete Reata Pharmaceuticals Inc. News Reata Pharmaceuticals Inc.

Market Cap 1B Todays Change -862 -294 Current Price 3117 Price as of April 18 2022 800 pm. View Reata Pharmaceuticals Inc RETA investment stock information. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below.

RETA Reports Q4 Loss Lags Revenue Estimates. Real time Reata Pharmaceuticals Inc. Key Stock Data PE Ratio TTM NA EPS TTM -819 Market Cap 130 B.

Cl A No significant news for in the past two years.

Reata Pharmaceuticals Inc Nasdaq Reta Shareholder Class Action Alert Bernstein Liebhard Llp Announces That A Securities Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc Nasdaq Reta

Reata Alert Bragar Eagel Squire P C Is Investigating Reata Pharmaceuticals Inc On Behalf Of Reata Stockholders And Encourages Investors To Contact The Firm

Reata Pharmaceuticals Inc Reta Stock Price News Info The Motley Fool

The Law Offices Of Frank R Cruz Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Reata Pharmaceuticals Inc Reta Business Wire